The bleeding disorder immune thrombocytopenic purpura (ITP) is a model for immunological research and new biological treatment modalities of chronic inflammatory and autoimmune disorders. In ITP, immunologically susceptible subjects are recognisable by disturbances of the immune response on various levels. Children have mostly a transient or persistent form (below 12 months' duration) and rarely have a chronic form of ITP. Children without bleedings may be observed without treatment or may need treatment according to a staging and management schedule (see Table 1 ).
Therapeutically, the immune cascade can be modulated on various levels by human immunoglobulins (Igs), anti-D Igs, corticosteroids, Tcell suppression, monoclonal anti-CD 20 or 52 antibodies or others.
Agonists stimulating growth of thrombopoietin-dependent cell lines that increase platelet counts might soon be available, mainly for patients with severe persistent, refractory or chronic ITP. This article highlights and updates immunopathological findings and proposes a management procedure for children with short-term or refractory ITP.
Definition and Incidence
ITP is a bleeding disorder characterised by platelet destruction due to The incidence in children with newly diagnosed ITP is estimated to be 5.3-5.7 patients per 100,000 children per year. 1,2 At diagnosis, 55% of boys and 45% of girls were registered prospectively; in infancy the number of boys was dramatically higher. 3 Incidence, duration and severity vary from continent to continent. A comparison between Vietnamese and European children with chronic ITP showed marked differences. 4
Pathophysiology of Immune Thrombocytopenic Purpura
In patients with ITP the maintenance of self-tolerance and the effective immune response seems to be altered in the presence of an inflammatory or autoimmune process. In ITP, circulating antibodies and/or immuncomplexes adsorb to the platelet specifically via the fragment antigen binding (Fab) region of the antibody to glycoprotein-epitopes on platelets or unspecifically via the Fc part of the IgG molecules, resulting in early opsonophagocytosis and destruction by macrophages. 5 The quantity of early platelet destruction and platelet production correlate with the degree of thrombocytopenia and bleeding.
In ITP and many other inflammatory and autoimmune disorders, multiple possibilities of disturbances on the different levels of the immune cascade are documented, especially in connection with intravenous Ig (IVIg) treatment: 6,7,8,9 on the level of antigen presentation, T-cell activation and signalling, B-cell regulation and antibodies/idiotypic antibodies production, activation/suppression of complement, opsonophagocytosis and apoptosis (see Table 2 ). These recognised alterations were used to develop new treatment modalities for many autoimmune disorders. A recent observation of ITP triggered by Helicobacter pylori illustrates the complexity of the immune response in susceptible patients, the host response and the country differences. 10, 11 The aetiology of ITP is still unknown, and why some children 23 Intracranial bleeding occurs in about 1:500-700 children, and is fatal in one-third. 24 The initial management (mean platelet counts) in ICIS registry I was as follows: about one-third of children received IVIG (8.1x10 9 /l) and one-third corticosteroids (13.3x10 9 /l), and the remaining one-third were observed (28.6x10 9 /l). 2 In children with persistent ITP of three to six months in duration, additional laboratory tests are recommended (see Table 1 ).
Unlike ITP in adults, persistent thrombocytopenia is observed in 20-30% of children and the rate of severe ITP is decreasing with duration of ITP (see Figure 1 ). In the above-mentioned registry I, follow-up data 12 months after diagnosis was evaluable for 308 children with persistent ITP at six months. 25 Between six and 12 months from diagnosis, 79 of the 308 children (25.6%) recovered with platelet counts above 150x10 9 /l, while 229 (74.4%) still had persistent ITP. The distribution of platelet counts at diagnosis at six and 12 months showed that the number of children with platelet counts below 10 and 20x10 9 /l markedly decreased within the first 12 months of diagnosis.
E U R O P E A N H A E M A T O L O G Y
Paediatric Haematology Thus, a reduction of severity of ITP over time was observed. In retrospective analyses, even after one year children recovered from their ITP. [26] [27] [28] [29] These observations raise the question whether the term 'chronic' ITP -now defined as persisting for six months after diagnosis -should be postponed to 12 months or longer. On the other hand, at 12 months after diagnosis in registry I, 11.3% of children still had platelet counts below 20x10 9 /l despite treatment. These children have refractory ITP.
Management
Since 1980, the therapeutic intervention of ITP has been challenged by the rapid effect of IVIG administration (see above). Today therapeutic approaches are targeted to the disturbed immune response (see Table   1 Table 2 and Figure 2 ).
While the infusion of IVIG or anti-D have rapid immunomodulatory effects (platelet increase within one to three days), the platelet stimulatory effect occurs five to 14 days after starting thrombopoietin agonist. In the near future, the stimulation of thrombopoiesis will eventually be an additional approach. For practical patient care a simple categorisation of the clinical severity of ITP is necessary and should be validated. A proposal is 'staging and management' based on bleedings 22 and quality of life 30 rather than on platelet counts (see Table 1 ). In stages 2 and 3, consensus between the individual patients and physicians should be reached. For interventional management the following procedures may be used. 31 Standard treatment includes: 32
• IVIG 0.4-0.8g/kg bodyweight (bw) once;
• anti-D Ig 50-75µg/kg bw once; 33, 34 • corticosteroids 4mg/kg bw daily for two to four days, then tapering for three days; and • (thrombopoietin-receptor agonist): 35-40 available in the US.
Where emergency treatment is needed in cases of severe lifethreatening bleeding, treatment should:
• begin with corticosteroids 30mg/kg bw or dexamethason 1-2mg/kg bw; 41 • progress to IVIG 0.8-1.0g/kg bw per dose; and 41 • include a platelet transfusion after the above measures.
In cases of refractory ITP, treatment should include:
• (thrombopoietin agonist): 35-40 available in the US;
• anti-CD 20-, anti-CD 52-monoclonal antibody for the suppression of B-cells; [42] [43] [44] [45] • cyclosporine A 2-5mg/kg bw per day tacrolimus for the suppression of T-cells;
• vincristin IV 1.5mg (2mg maximum)/m 2 four to six times weekly plus 2mg corticosteroid/kg/bw/day three times per week;
• interferon, mycophenolate mofetil, 46 high-dose corticosteroids or dexamethasone should also be considered; 47 • splenectomy; and 48 • classic options (individual indications) such as azathioprime and cyclophosphamide.
Clinical Research
There is a considerable amount of convincing evidence-based data available on incidence, demographics, natural history and managements of ITP. Retrospective case series, surveys, 49, 50 guidelines, 51, 52 
